ARESTIN® + SRP: Therapeutic Drug Concentrations Lead to Better Clinical Outcomes Than SRP Alone for up to 90 days

Adding ARESTIN® significantly improves patient outcomes at all clinical endpoints

Reduction in periodontal pockets with Arestin®

With one treatment, ARESTIN® + SRP provides significantly better results than SRP alone for up to 90 days between office visits

Adding ARESTIN® is proven effective for periodontal maintenance patients

70% of pockets not responding to initial SRP were reduced with ARESTIN®

Approximately half of pockets not responding to initial SRP were reduced with ARESTIN®

Adding ARESTIN® is proven effective, even in higher-risk patient groups and in difficult-to-treat areas

Chart based on periodontal disease reduction scores

For full safety information, click here.

ARESTIN® is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION

ARESTIN® should not be used in any patient who has a known sensitivity to minocycline or tetracyclines. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth, and therefore should not be used in children or in pregnant or nursing women. Hypersensitivity reactions that included, but were not limited to, anaphylaxis, angioneurotic edema, urticaria, rash, swelling of the face and pruritus have been reported with the use of ARESTIN®. In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome and pain.

Please see Full Prescribing Information

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Contact us with questions about your account or MyArestin.com